Marine Ingredients acquires softgel production facility
Employees currently working in Miami will transfer to Innova Softgel, a newly formed subsidiary of Marine Ingredients.
Aenova Group has signed a definitive agreement to sell Swiss Caps USA’s softgel manufacturing facility in Miami, FL, to Marine Ingredients, a leading omega-3 manufacturer. As part of the agreement, the employees currently working in Miami will transfer from Swiss Caps USA to Innova Softgel, LLC, a newly formed subsidiary of Marine Ingredients. Both parties agreed not to disclose financial details of the transaction, which is expected to be closed by the end of December.
"The Swiss Caps acquisition is very attractive to us for a number of reasons. First and foremost, is the talented Swiss Caps team of seasoned professionals who take pride in producing high quality products for a broad spectrum of US and international customers — servicing these customers will remain their focus. Additionally, Marine Ingredients will gain the last piece in our quest to be fully vertically-integrated, improving the traceability and transparency of the entire supply chain for customers. Finally, because of Swiss Caps' various certifications and licenses, including OTC, TGA, NSF, Halal and MSC, we will be better able to serve the market as global business opportunities are pursued,” said Olav Sandnes, President of Marine Ingredients.
“We are extremely pleased to find a strong organization such as Marine Ingredients to carry on the future success of the Miami site,” stated Marcus Boening, CFO, Aenova Group.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.